June 15th, 2011
Johnson & Johnson Steps Out of the Stent Market
Larry Husten, PHD
Johnson & Johnson announced today that it is exiting the stent business. The company will discontinue development of its Nevo sirolimus-eluting stent and will end sales of its Cypher family of stents by the end of the year. The company was the manufacturer of both the first stent, the Palmaz-Schatz stent, in the 1990s and the first drug-eluting stent, the Cypher stent, in the early 2000s.
One Response to “Johnson & Johnson Steps Out of the Stent Market”
NEJM Journal Watch — Recent Cardiology Articles- Intensive vs. Standard Blood Pressure Lowering in Patients with Diabetes
- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
Anyone know WHY?